Submission on the Right to Access and Take Part in Scientific Progress
TAG is a longstanding champion of the human right to science, which we believe entitles everyone, everywhere to benefit from the best available tools to end HIV, TB, and HCV.
An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis
An updated, version of this publication was released in 2025. In 2022, the World Health Organization (WHO) updated its guidelines for treating drug-resistant tuberculosis (DR-TB), recommending a six-month cure. This guide lays out what activists need to know about the…
ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.
Treatment Action Group Calls for Immediate Ceasefire in Gaza to Protect Health and Lives
Treatment Action Group (TAG) urgently calls for an immediate ceasefire in Gaza. We grieve Israeli and Palestinian lives lost before, on, and since October 7, and unequivocally condemn the Hamas attacks that killed more than 1,400 Israelis, including some 30 children.
TAG Condemns GSK Actions Surrounding Potential TB Vaccine Revealed by Bombshell ProPublica Report
TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.
TAGline October 2023
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.
TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline
TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.
TAG Remarks Submitted to United Nation High-Level Meetings (UN HLMs), September 2023
TAG prepared these remarks to deliver at United Nations High-Level Meetings (UN HLMs) on tuberculosis (TB), universal health coverage (UHC), and pandemic prevention, preparedness, and response (PPR). While we welcome public reaffirmation of commitments to end TB, we urge member…
TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR
TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.
New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN
As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.